SCHEMBL14140366

SCHEMBL14140366

CNCCNc1nccc(-c2ccnc(Nc3cccc(N)c3)n2)c1C

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABL1 P00519 4/20 0.52
BCR P11274 3/20 0.52
SRC P12931 3/20 0.52
CDK2 P24941 2/20 0.52
CDK4 P11802 1/20 0.52
CDK5 Q00535 2/20 0.50
EGFR P00533 1/20 0.50
PRKACA P17612 1/20 0.50
PRKACG P22612 1/20 0.50
PRKACB P22694 1/20 0.50
CAMK2D Q13557 2/20 0.47
PIK3CA P42336 2/20 0.43
PIK3CG P48736 2/20 0.43
PIK3CB P42338 1/20 0.43
MEN1 O00255 1/20 0.43
NPC1 O15118 1/20 0.43
RAB9A P51151 1/20 0.43
KMT2A Q03164 1/20 0.43
CDK5R1 Q15078 1/20 0.43
PLK1 P53350 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3609491 0.88 CAMK2D (0.53) ABL1BCRCDK2CDK4CDK5
SCHEMBL3602192 0.80 CAMK2D (0.58) ABL1BCRCDK2CDK4CDK5
SCHEMBL3609046 0.76 CDK1 (0.65) ABL1BCRCDK2CDK4CDK5
SCHEMBL3608406 0.75 CAMK2D (0.53) ABL1BCRCDK2CDK4CDK5
SCHEMBL3597064 0.75 PIK3CA (0.52) ABL1BCRCDK2CDK4CDK5
SCHEMBL3610719 0.74 CAMK2D (0.54) ABL1BCRCDK2CDK4CDK5
SCHEMBL14140367 0.74 ABL1 (0.48) ABL1BCRSRCCDK2CDK4
SCHEMBL14140481 0.73 CAMK2D (0.49) ABL1BCRCDK2CDK4CDK5
SCHEMBL14140620 0.73 ABL1 (0.50) ABL1BCRSRCCDK2CDK4
SCHEMBL3607290 0.73 ABL1 (0.43) ABL1BCRSRCCDK2EGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2008079933-A2 HETEROARYL-HETEROARYL COMPOUNDS AS CDK INHIBITORS FOR THE TREATMENT OF CANCER, INFLAMMATION AND VIRAL INFECTIONS NOVARTIS AG (CH) 2008-07-03 WO disclosed